Class action alleges “no-generics” collusion by Gilead
Several activists and two employee benefit funds have sued Gilead and three other drugmakers for allegedly colluding to limit generic competition for treatment of human immunodeficiency virus.
Subscribe to Global Competition Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Competition Review experts.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10